Results 1 to 10 of about 6,967,236 (252)

Overcoming Drug Resistance by Paclitaxel Resistance in Triple-Negative Breast Cancer. [PDF]

Adv Sci (Weinh)
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Chen B, Wang Y, Li T, Guo C, Xie Z, Zhang Z, Han X, Wang W, Wang J, Ma X, Min Y.   +10 more
europepmc   +2 more sources

Epigenetic Reactivation of TNFRSF19 Suppresses Mitophagy and Sensitizes Triple-Negative Breast Cancer to Doxorubicin. [PDF]

Adv Sci (Weinh)
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Liu S, Liu C, Zheng W, Tong X, Gui Z, Lu Z, Ieong S, Zhang L.   +7 more
europepmc   +2 more sources

Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer

Journal for ImmunoTherapy of Cancer, 2022
Background Triple-negative breast cancer is characterized by a poor prognosis and lack of targeted treatments, and thus, new targeting markers and therapeutic strategies are urgently needed.
Cong Chen, Linbo Wang, Xun Zhang, Ling Xu, Misha Mao, Yongxia Chen, Jingjing Yang, Yifan Cheng, Feiyang Ji, Jichun Zhou, Zhaoqing Li, Siwei Ju, Jiahang Zhang   +12 more
doaj   +1 more source

Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy. [PDF]

PLoS ONE, 2015
Triple-negative breast cancer is a high-risk breast cancer with poor survival rate. To date, there is a lack of targeted therapy for this type of cancer. One unique phenomenon is that inflammatory breast cancer is frequently triple negative.
Zining Jin, Wenqian Wang, Nan Jiang, Lei Zhang, Yiming Li, Xiaoyin Xu, Shouliang Cai, Liang Wei, Xuhong Liu, Guanglei Chen, Yizhen Zhou, Cheng Liu, Zhan Li, Feng Jin, Bo Chen   +14 more
doaj   +1 more source

YTHDC1 Orchestrates Glucose and Glutamate Rewiring to Overcome Lethal Metabolic Stress in Triple-Negative Breast Cancer. [PDF]

Adv Sci (Weinh)
Lai et al. find that m6A reader YTHDC1 is specifically overexpressed in triple‐negative breast cancer (TNBC) and orchestrates glucose and glutamine metabolism in an m6A‐dependent manner to confer robust adaptability to lethal metabolic stress. Leveraging YTHDC1 knockdown‐induced metabolic vulnerability, an ATF4 mRNA‐targeted nanotherapy is developed to
Lai ZH, Wang Y, Li NN, Zeng L, Liu R, Li X, Li C, Ma XY, Fu W, Tang Y, Chen J, Liao N, Luo ML.   +12 more
europepmc   +2 more sources

Metabolic Reprogramming in Triple-Negative Breast Cancer

Frontiers in Oncology, 2020
Metabolic reprogramming is an emerging hallmark of cancer cells, in which cancer cells exhibit distinct metabolic phenotypes to fuel their proliferation and progression.
Xiangyu Sun, Mozhi Wang, Mengshen Wang, Xueting Yu, Jingyi Guo, Tie Sun, Xinyan Li, Litong Yao, Haoran Dong, Yingying Xu   +9 more
doaj   +1 more source

HJURP regulates cell proliferation and chemo-resistance via YAP1/NDRG1 transcriptional axis in triple-negative breast cancer

Cell Death and Disease, 2022
Triple-negative breast cancer is still a difficult point in clinical treatment at present, and a deep study of its pathogenesis has great clinical value. Therefore, our research mainly focuses on exploring the progression of triple-negative breast cancer
Misha Mao, Yunlu Jia, Yongxia Chen, Jingjing Yang, Ling Xu, Xun Zhang, Jichun Zhou, Zhaoqing Li, Cong Chen, Siwei Ju, Linbo Wang   +10 more
doaj   +1 more source

Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. [PDF]

PLoS ONE, 2012
BackgroundTriple-negative breast cancer is a subtype of breast cancer with aggressive tumor behavior and distinct disease etiology. Due to the lack of an effective targeted medicine, treatment options for triple-negative breast cancer are few and ...
Wen-Hung Kuo, Yao-Yin Chang, Liang-Chuan Lai, Mong-Hsun Tsai, Chuhsing Kate Hsiao, King-Jen Chang, Eric Y Chuang   +6 more
doaj   +1 more source

MiR-133 Targets YES1 and Inhibits the Growth of Triple-Negative Breast Cancer Cells

Technology in Cancer Research & Treatment, 2020
Triple-negative breast cancer shows worse outcome compared with other subtypes of breast cancer. The discovery of dysregulated microRNAs and their roles in the progression of triple-negative breast cancer provide novel strategies for the treatment of ...
Guochen Zhang MD, Junlan Wang BS, Ruilin Zheng MD, Beibei Song BS, Li Huang PhD, Yujiang Liu MD, Yating Hao MD, Xiangdong Bai PhD   +7 more
doaj   +1 more source

Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer

Frontiers in Pharmacology, 2021
Triple-negative breast cancers are heterogeneous, poorly prognostic, and metastatic malignancies that result in a high risk of death for patients. Targeted therapy for triple-negative breast cancer has been extremely challenging due to the lack of ...
Wenjie Zhao, Wenjie Zhao, Jinhua Liu, Yaqun Li, Zichao Chen, Zichao Chen, Dongmei Qi, Dongmei Qi, Zhen Zhang   +8 more
doaj   +1 more source